197 related articles for article (PubMed ID: 34462429)
1. CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1.
Luo H; Zhou Z; Huang S; Ma M; Zhao M; Tang L; Quan Y; Zeng Y; Su L; Kim J; Zhang P
Cell Death Dis; 2021 Aug; 12(9):820. PubMed ID: 34462429
[TBL] [Abstract][Full Text] [Related]
2. CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells.
Wu W; Zhao J; Xiao J; Wu W; Xie L; Xie X; Yang C; Yin D; Hu K
Biochem Biophys Res Commun; 2021 Oct; 573():62-68. PubMed ID: 34388456
[TBL] [Abstract][Full Text] [Related]
3. CHFR‑mediated epithelial‑to‑mesenchymal transition promotes metastasis in human breast cancer cells.
Jiang G; Fang H; Shang X; Chen X; Cao F
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33880594
[TBL] [Abstract][Full Text] [Related]
4. ZEB1 induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the progression of triple negative breast cancer by binding with ELAVL1 to maintain the stability of ZEB1 mRNA.
Luo N; Zhang K; Li X; Hu Y
J Cell Biochem; 2020 Oct; 121(10):4176-4187. PubMed ID: 31922280
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
[TBL] [Abstract][Full Text] [Related]
6. CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation.
Kashima L; Idogawa M; Mita H; Shitashige M; Yamada T; Ogi K; Suzuki H; Toyota M; Ariga H; Sasaki Y; Tokino T
J Biol Chem; 2012 Apr; 287(16):12975-84. PubMed ID: 22337872
[TBL] [Abstract][Full Text] [Related]
7. Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells.
Woo SR; Lee HJ; Oh SJ; Kim S; Park SH; Lee J; Song KH; Kim TW
Biochem Biophys Res Commun; 2018 Sep; 503(3):1812-1818. PubMed ID: 30060952
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.
Zhang X; Feng Y; Wang XY; Zhang YN; Yuan CN; Zhang SF; Shen YM; Fu YF; Zhou CY; Li X; Cheng XD; Lu WG; Xie X
Cell Death Dis; 2018 Jan; 9(2):93. PubMed ID: 29367628
[TBL] [Abstract][Full Text] [Related]
9. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2.
Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z
Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785
[TBL] [Abstract][Full Text] [Related]
10. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
[TBL] [Abstract][Full Text] [Related]
11. CHFR negatively regulates SIRT1 activity upon oxidative stress.
Kim M; Kwon YE; Song JO; Bae SJ; Seol JH
Sci Rep; 2016 Nov; 6():37578. PubMed ID: 27883020
[TBL] [Abstract][Full Text] [Related]
12. Chfr is linked to tumour metastasis through the downregulation of HDAC1.
Oh YM; Kwon YE; Kim JM; Bae SJ; Lee BK; Yoo SJ; Chung CH; Deshaies RJ; Seol JH
Nat Cell Biol; 2009 Mar; 11(3):295-302. PubMed ID: 19182791
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.
Privette LM; González ME; Ding L; Kleer CG; Petty EM
Cancer Res; 2007 Jul; 67(13):6064-74. PubMed ID: 17596595
[TBL] [Abstract][Full Text] [Related]
14. The anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by ring finger domain.
Fukuda T; Kondo Y; Nakagama H
PLoS One; 2008 Mar; 3(3):e1776. PubMed ID: 18335050
[TBL] [Abstract][Full Text] [Related]
15. Nuclear localization of Chfr is crucial for its checkpoint function.
Kwon YE; Kim YS; Oh YM; Seol JH
Mol Cells; 2009 Mar; 27(3):359-63. PubMed ID: 19326084
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of ZEB1 suppressed the formation of vasculogenic mimicry and epithelial-mesenchymal transition in the human breast cancer cell line MDA-MB-231.
Liang W; Song S; Xu Y; Li H; Liu H
Mol Med Rep; 2018 May; 17(5):6711-6716. PubMed ID: 29512767
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
18. CHFR: a key checkpoint component implicated in a wide range of cancers.
Sanbhnani S; Yeong FM
Cell Mol Life Sci; 2012 May; 69(10):1669-87. PubMed ID: 22159584
[TBL] [Abstract][Full Text] [Related]
19. SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer.
Tang H; Chen B; Liu P; Xie X; He R; Zhang L; Huang X; Xiao X; Xie X
Carcinogenesis; 2019 Oct; 40(10):1278-1287. PubMed ID: 30810729
[TBL] [Abstract][Full Text] [Related]
20. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]